Director, Breast and Gynecological Cancer Surveillance, Surveillance and Health Services Research, American Cancer Society, Atlanta, GAAssistant Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GAVice President, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.Director, Breast and Gynecological Cancer Surveillance, Surveillance and Health Services Research, American Cancer Society, Atlanta, GAAssistant Professor of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GAVice President, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA.Use the link below to share a full-text version of this article with your friends and colleagues.
Rarissimes sont les hommes, comme Poincaré et Einstein, aptes à créer ou à manier les instruments logiques, les prodigieux appareils d'abréviations qui permettent de refouler, de contraindre l'infinie diversité des faits (Valéry, Entret. Name must be less than 100 characters
2011 Nov;47(17):2493-511. doi: 10.1016/j.ejca.2011.08.008. Elsevier Science Epub 2017 Jul 4.Gatta G, Capocaccia R, Trama A, Martínez-García C; RARECARE Working Group.Adv Exp Med Biol. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group.Eur J Cancer. The RARECARE group conducted a sensitivity analysis and concluded that the vast majority of NOS cases in Europe were due to genuine difficulties in assigning more specific diagnoses.Collectively, rare cancers contribute to a substantial portion of the cancer burden in the United States.
− Très rare, qui n'existe qu'en très peu d'exemplaires ou en très petite quantité.
Screening of rare cancer sites is generally impractical because of the extremely large numbers of patients that would need to be screened to prevent one death.There are several limitations in this analysis of rare cancers.
It may be more difficult to diagnose and register rare cancers than common cancers. avec F. Lefèvre, 1926, p. 141). Purpose. Five‐Year Relative Survival for Rare and Common Cancers by Age at Diagnosis (Years), 2006 Through 2012, United States.Source: Surveillance, Epidemiology, and End Results (SEER) Program, 18 SEER Registries, National Cancer Institute, 2016.The proportion of late (regional/distant) stage diagnoses and the 1‐year and 5‐year relative survival rates for select rare cancers are provided in Table In this report, we provide an overview of the burden of rare cancers in the United States. Of course, some rare histologic subtypes of more common cancer sites, such as rare subtypes of adenocarcinoma of the breast, are detectable through current screening modalities.